selinexor-话题@MedSci - 梅斯（MedSci）

#selinexor#

13篇内容 | 1135人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1531280, encodeId=ad27153128072, content=<a href='/topic/show?id=bb4d1611ea2' target=_blank style='color:#2F92EE;'>#selinexor#</a>, objectTitle=Clin Cancer Res：口服Selinexor治疗复发性胶质母细胞瘤的疗效, objectType=article, longId=295055, objectId=f6e229505515, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6e229505515, replyNumber=0, likeNumber=66, createdTime=2022-02-04, rootId=0, userName=zhixianchen, userId=9b6c12239440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6e229505515, moduleTitle=Clin Cancer Res：口服Selinexor治疗复发性胶质母细胞瘤的疗效, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f6e229505515)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531279, encodeId=a3a515312e9e8, content=<a href='/topic/show?id=bb4d1611ea2' target=_blank style='color:#2F92EE;'>#selinexor#</a>, objectTitle=Clin Cancer Res：口服Selinexor治疗复发性胶质母细胞瘤, objectType=article, longId=292164, objectId=e7c829216496, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e7c829216496, replyNumber=0, likeNumber=65, createdTime=2021-12-19, rootId=0, userName=zhixianchen, userId=9b6c12239440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e7c829216496, moduleTitle=Clin Cancer Res：口服Selinexor治疗复发性胶质母细胞瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e7c829216496)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531278, encodeId=8d2815312e8b1, content=<a href='/topic/show?id=bb4d1611ea2' target=_blank style='color:#2F92EE;'>#selinexor#</a>, objectTitle=Clin Cancer Res：口服Selinexor治疗复发性胶质母细胞瘤, objectType=article, longId=220259, objectId=ae6b22025996, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae6b22025996, replyNumber=0, likeNumber=71, createdTime=2021-11-14, rootId=0, userName=zhixianchen, userId=9b6c12239440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae6b22025996, moduleTitle=Clin Cancer Res：口服Selinexor治疗复发性胶质母细胞瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=ae6b22025996)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531277, encodeId=3b4815312e7bf, content=<a href='/topic/show?id=bb4d1611ea2' target=_blank style='color:#2F92EE;'>#selinexor#</a>, objectTitle=J Hematol Oncol：塞利尼索(selinexor)治疗复发/难治性弥漫大B淋巴细胞瘤的疗效：SADAL研究, objectType=article, longId=215018, objectId=3aeb21501886, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3aeb21501886, replyNumber=0, likeNumber=131, createdTime=2021-07-31, rootId=0, userName=zhixianchen, userId=9b6c12239440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3aeb21501886, moduleTitle=J Hematol Oncol：塞利尼索(selinexor)治疗复发/难治性弥漫大B淋巴细胞瘤的疗效：SADAL研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3aeb21501886)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531276, encodeId=6ba115312e60a, content=<a href='/topic/show?id=bb4d1611ea2' target=_blank style='color:#2F92EE;'>#selinexor#</a>, objectTitle=FDA批准Karyopharm的Xpovio（selinexor）用于治疗多发性骨髓瘤, objectType=article, longId=204714, objectId=6286204e1417, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6286204e1417, replyNumber=0, likeNumber=76, createdTime=2020-12-22, rootId=0, userName=zhixianchen, userId=9b6c12239440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6286204e1417, moduleTitle=FDA批准Karyopharm的Xpovio（selinexor）用于治疗多发性骨髓瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6286204e1417)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531275, encodeId=f01b15312e567, content=<a href='/topic/show?id=bb4d1611ea2' target=_blank style='color:#2F92EE;'>#selinexor#</a>, objectTitle=骨髓瘤治疗新进展，全新作用机制药物Selinexor（ATG-010）三种治疗方案入选更新版NCCN®多发性骨髓瘤诊疗指南, objectType=article, longId=204590, objectId=39b1204590b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39b1204590b5, replyNumber=0, likeNumber=85, createdTime=2020-12-18, rootId=0, userName=zhixianchen, userId=9b6c12239440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39b1204590b5, moduleTitle=骨髓瘤治疗新进展，全新作用机制药物Selinexor（ATG-010）三种治疗方案入选更新版NCCN®多发性骨髓瘤诊疗指南, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=39b1204590b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531274, encodeId=37c515312e40e, content=<a href='/topic/show?id=bb4d1611ea2' target=_blank style='color:#2F92EE;'>#selinexor#</a>, objectTitle=ATG-010（selinexor）完成首例复发难治性外周T和NK/T细胞淋巴瘤患者给药, objectType=article, longId=200687, objectId=397520068ed0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397520068ed0, replyNumber=0, likeNumber=65, createdTime=2020-09-16, rootId=0, userName=zhixianchen, userId=9b6c12239440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397520068ed0, moduleTitle=ATG-010（selinexor）完成首例复发难治性外周T和NK/T细胞淋巴瘤患者给药, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=397520068ed0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531273, encodeId=426c15312e30c, content=<a href='/topic/show?id=bb4d1611ea2' target=_blank style='color:#2F92EE;'>#selinexor#</a>, objectTitle=第17届国际骨髓瘤研讨会（IMW）：XPOVIO（Selinexor）的全新临床数据将被披露, objectType=article, longId=179536, objectId=b7571e9536db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7571e9536db, replyNumber=0, likeNumber=101, createdTime=2019-09-18, rootId=0, userName=zhixianchen, userId=9b6c12239440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7571e9536db, moduleTitle=第17届国际骨髓瘤研讨会（IMW）：XPOVIO（Selinexor）的全新临床数据将被披露, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b7571e9536db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531272, encodeId=96c315312e2b4, content=<a href='/topic/show?id=bb4d1611ea2' target=_blank style='color:#2F92EE;'>#selinexor#</a>, objectTitle=NEJM：XPOVIO（Selinexor）治疗难治性多发性骨髓瘤的IIb期STORM研究, objectType=article, longId=178110, objectId=262c1e81109b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=262c1e81109b, replyNumber=0, likeNumber=99, createdTime=2019-08-24, rootId=0, userName=zhixianchen, userId=9b6c12239440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=262c1e81109b, moduleTitle=NEJM：XPOVIO（Selinexor）治疗难治性多发性骨髓瘤的IIb期STORM研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=262c1e81109b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531271, encodeId=f00515312e1fb, content=<a href='/topic/show?id=bb4d1611ea2' target=_blank style='color:#2F92EE;'>#selinexor#</a>, objectTitle=Blood：Selinexor联合低剂量硼替佐米和地塞米松（SVd）用于复发性/难治性多发性骨髓瘤的疗效和安全性, objectType=article, longId=151955, objectId=4deb1519558a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4deb1519558a, replyNumber=0, likeNumber=64, createdTime=2018-10-28, rootId=0, userName=zhixianchen, userId=9b6c12239440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4deb1519558a, moduleTitle=Blood：Selinexor联合低剂量硼替佐米和地塞米松（SVd）用于复发性/难治性多发性骨髓瘤的疗效和安全性, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4deb1519558a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531270, encodeId=fca615312e0b2, content=<a href='/topic/show?id=bb4d1611ea2' target=_blank style='color:#2F92EE;'>#selinexor#</a>, objectTitle=Blood: selinexor治疗急性骨髓性白血病的I期临床试验, objectType=article, longId=102914, objectId=1daa10291491, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1daa10291491, replyNumber=0, likeNumber=75, createdTime=2017-06-23, rootId=0, userName=zhixianchen, userId=9b6c12239440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1daa10291491, moduleTitle=Blood: selinexor治疗急性骨髓性白血病的I期临床试验, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1daa10291491)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531269, encodeId=9a35153126997, content=<a href='/topic/show?id=bb4d1611ea2' target=_blank style='color:#2F92EE;'>#selinexor#</a>, objectTitle=Blood:一期临床试验表明Selinexor对非霍奇金淋巴瘤具有良好的治疗效果, objectType=article, longId=102652, objectId=a76410265205, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a76410265205, replyNumber=0, likeNumber=62, createdTime=2017-06-22, rootId=0, userName=zhixianchen, userId=9b6c12239440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a76410265205, moduleTitle=Blood:一期临床试验表明Selinexor对非霍奇金淋巴瘤具有良好的治疗效果, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a76410265205)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1531268, encodeId=c19c15312688c, content=<a href='/topic/show?id=bb4d1611ea2' target=_blank style='color:#2F92EE;'>#selinexor#</a>, objectTitle=ASCO 2016：Selinexor组合疗法有望治疗复发且难治的多发性骨髓瘤, objectType=article, longId=70341, objectId=f48ae0341e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f48ae0341e9, replyNumber=0, likeNumber=95, createdTime=2016-06-11, rootId=0, userName=zhixianchen, userId=9b6c12239440, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f48ae0341e9, moduleTitle=ASCO 2016：Selinexor组合疗法有望治疗复发且难治的多发性骨髓瘤, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f48ae0341e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

selinexor

2020-05-29

zhixianchen (审核中...)

前往app查看评论内容

#selinexor#

Clin Cancer Res：口服Selinexor治疗复发性胶质母细胞瘤的疗效

2022-02-04

zhixianchen (审核中...)

前往app查看评论内容

#selinexor#

Clin Cancer Res：口服Selinexor治疗复发性胶质母细胞瘤

2021-12-19

zhixianchen (审核中...)

前往app查看评论内容

#selinexor#

Clin Cancer Res：口服Selinexor治疗复发性胶质母细胞瘤

2021-11-14

zhixianchen (审核中...)

前往app查看评论内容

#selinexor#

J Hematol Oncol：塞利尼索(selinexor)治疗复发/难治性弥漫大B淋巴细胞瘤的疗效：SADAL研究

2021-07-31

zhixianchen (审核中...)

前往app查看评论内容

#selinexor#

FDA批准Karyopharm的Xpovio（selinexor）用于治疗多发性骨髓瘤

2020-12-22

zhixianchen (审核中...)

前往app查看评论内容

#selinexor#

骨髓瘤治疗新进展，全新作用机制药物Selinexor（ATG-010）三种治疗方案入选更新版NCCN®多发性骨髓瘤诊疗指南

2020-12-18

zhixianchen (审核中...)

前往app查看评论内容

#selinexor#

ATG-010（selinexor）完成首例复发难治性外周T和NK/T细胞淋巴瘤患者给药

2020-09-16

zhixianchen (审核中...)

前往app查看评论内容

#selinexor#

第17届国际骨髓瘤研讨会（IMW）：XPOVIO（Selinexor）的全新临床数据将被披露

2019-09-18

zhixianchen (审核中...)

前往app查看评论内容

#selinexor#

NEJM：XPOVIO（Selinexor）治疗难治性多发性骨髓瘤的IIb期STORM研究

2019-08-24

zhixianchen (审核中...)

前往app查看评论内容

#selinexor#

Blood：Selinexor联合低剂量硼替佐米和地塞米松（SVd）用于复发性/难治性多发性骨髓瘤的疗效和安全性

2018-10-28

zhixianchen (审核中...)

前往app查看评论内容

#selinexor#

Blood: selinexor治疗急性骨髓性白血病的I期临床试验

2017-06-23

zhixianchen (审核中...)

前往app查看评论内容

#selinexor#

Blood:一期临床试验表明Selinexor对非霍奇金淋巴瘤具有良好的治疗效果

2017-06-22

zhixianchen (审核中...)

前往app查看评论内容

#selinexor#

ASCO 2016：Selinexor组合疗法有望治疗复发且难治的多发性骨髓瘤

2016-06-11

科室
- - 订阅+
  - 更多科室
工具
服务